GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (SZSE:002399) » Definitions » Sale Of Investment

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Sale Of Investment : ¥884 Mil (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Sale Of Investment?

Shenzhen Hepalink Pharmaceutical Group Co's sale of investment for the three months ended in Mar. 2024 was ¥437 Mil. It means Shenzhen Hepalink Pharmaceutical Group Co gained ¥437 Mil from selling investments. Shenzhen Hepalink Pharmaceutical Group Co's sale of investment for the trailing twelve months (TTM) ended in Mar. 2024 was ¥884 Mil.

Compared with last quarter (¥120 Mil in Dec. 2023 ), Shenzhen Hepalink Pharmaceutical Group Co gained more money from selling investments in Mar. 2024 (¥437 Mil).


Shenzhen Hepalink Pharmaceutical Group Co Sale Of Investment Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Sale Of Investment Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,914.09 1,027.03 3,305.13 4,210.72 1,647.35

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,199.85 249.83 77.54 120.12 436.92

Shenzhen Hepalink Pharmaceutical Group Co Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥884 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhen Hepalink Pharmaceutical Group Co Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Business Description

Traded in Other Exchanges
Address
No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.
Executives
Zhang Ping Director
Li Li Director
Kong Yun Executives
Li Tan Directors, executives

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Headlines

No Headlines